التفاصيل البيبلوغرافية
| العنوان: |
Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards. |
| المؤلفون: |
SENIOR, MELANIE Melanie.Senior@RealEndpoints.com |
| المصدر: |
IN VIVO. Jun2013, Vol. 31 Issue 6, p26-31. 6p. |
| مصطلحات موضوعية: |
*ANTIHYPERTENSIVE agents industry, *DRUG patents, DRUG development, PATENT expiration |
| الشركة/الكيان: |
ACTELION Pharmaceuticals Ltd. |
| مستخلص: |
The article focuses on the efficacy standard for the pulmonary arterial hypertension (PAH) drug market being set by Actelion Pharmaceuticals Ltd. in preparation for the patent expiry of its leading PAH drug, Tracleer (bosentan). An overview is given on the PAH drug manufactured by Actelion which makes 90% of the company's revenue. It describes the two replacement PAH drugs being developed by the company. It discusses the move of Actelion to further improve its life cycle management strategy. INSET: PAH DRUG TYPES, TREATMENT PATHWAYS. |
| قاعدة البيانات: |
Business Source Index |
